Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

KPV peptide icon, one bubble per amino acidKPV3 residuesKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.

KPV

ImmunePreclinical
30 min half-life·Injection/Oral

Also known as: alpha-MSH(11-13), α-MSH C-terminal tripeptide

Get an alert when FDA rules on KPV

Follow every legal or FDA change, KPV included. By default, alerts come as one weekly push that names the peptides.

Three amino acids. That's the entire molecule. The KPV peptide (Lysine-Proline-Valine) is a tripeptide fragment from the tail end of alpha-melanocyte stimulating hormone, and it shuts down NF-kB, the master switch behind gut inflammation. Mouse colitis models show it enters inflamed intestinal cells through the PepT1 transporter, which gets upregulated in damaged tissue. No human clinical trial has been completed. Zero. But the preclinical mechanism is clean, community reports across IBD and IBS forums track closely with the animal data, and it's one of the few peptides that works orally for gut-specific conditions. Most users run 8-week cycles at 200 to 500 mcg per day subcutaneous or 500 to 1,500 mcg oral.

What Is KPV?

KPV (Lysine-Proline-Valine, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone and one of the most discussed anti-inflammatory peptides in the gut health community. It doesn't bind melanocortin receptors the way full-length alpha-MSH does. Instead, it enters cells through PepT1, a di/tripeptide transporter expressed in the small intestine.

The targeting gets interesting during active inflammation. PepT1 expression increases in inflamed colonic epithelium, confirmed in both Caco2-BBE cell lines and mouse colitis models (Dalmasso et al., Gastroenterology 2008)[1]. Inflamed tissue absorbs more KPV than healthy tissue. Once inside the cell, KPV inhibits NF-kB nuclear translocation at nanomolar concentrations, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8.

Community use mirrors the preclinical rationale almost exactly. Oral dosing at 500 to 1,500 mcg per day on an empty stomach is the standard protocol for IBD, IBS, and leaky gut. Subcutaneous injection at 200 to 500 mcg per day covers systemic inflammation. The BPC-157 stack is the most discussed combination; KPV handles the inflammatory signaling while BPC-157 drives mucosal repair. Multiple integrative medicine clinics recommend this pairing.

The honest limitation: every dose recommendation comes from mouse data extrapolation and community trial-and-error. No human pharmacokinetic study has measured oral bioavailability. No dose-finding trial has been completed. The plasma half-life (~30 minutes) is estimated from alpha-MSH family kinetics, not from direct KPV measurement. Fifteen PubMed papers cover this peptide. The FDA has stated it lacks human exposure data for any administration route. That gap between clean preclinical science and absent human validation defines where KPV sits right now.

How KPV Works

KPV bypasses melanocortin receptors entirely. Unlike full-length alpha-MSH, this tripeptide enters cells through PepT1, a proton-coupled transporter that normally imports dietary dipeptides and tripeptides across intestinal epithelium.

PepT1 expression is low in healthy colonic tissue but climbs during active inflammation [1]. That upregulation creates a built-in targeting system. Inflamed epithelial cells, macrophages, and immune cells absorb KPV preferentially. Dalmasso and colleagues confirmed this uptake in Caco2-BBE intestinal cells and in mouse colitis models.

Once inside the cell, KPV blocks NF-kB activation at nanomolar concentrations. It prevents the nuclear translocation of this transcription factor, which sits upstream of most inflammatory cytokine production. The downstream effect: reduced TNF-alpha, IL-1beta, IL-6, and IL-8 output. MAP kinase signaling is also suppressed. Anti-inflammatory IL-10 stays intact or increases.

KPV also reduces adhesion molecule and chemokine receptor expression on immune cells. Fewer inflammatory cells migrate to damaged tissue. In colonic epithelium specifically, it decreases epithelial apoptosis and helps restore barrier integrity. Hyaluronic acid-functionalized nanoparticles loaded with KPV showed even greater colitis reduction in a 2017 study (Xiao et al., Mol Ther)[2].

The functional anti-inflammatory window extends well past the ~30 minute plasma half-life. Intracellular NF-kB suppression persists for 4 to 6 hours after uptake, which is why once-daily dosing works despite rapid plasma clearance.

KPV Benefits

  • KPV benefits center on targeted gut inflammation control and immune modulation through NF-kB suppression.
  • Potent NF-kB inhibition at nanomolar concentrations, confirmed in intestinal epithelial cell lines and mouse colitis models [1]. This blocks the master inflammatory switch upstream of most cytokine production.
  • Preferential uptake by inflamed tissue. PepT1 transporter expression increases during intestinal inflammation, creating a natural targeting mechanism. Healthy tissue absorbs less; damaged tissue absorbs more.
  • Oral dosing option for gut-specific delivery. One of the few injectable peptides that also works orally. Community users report reduced bloating, improved stool consistency, and decreased gut pain within 2 to 4 weeks on oral protocols.
  • Broad anti-inflammatory cytokine suppression covering TNF-alpha, IL-1beta, IL-6, and IL-8, while preserving anti-inflammatory IL-10 levels. Multiple pathway inhibition (NF-kB plus MAP kinase) rather than single-target blockade.
  • Strong tolerability profile across community reports, with minimal side effects at standard doses (200 to 500 mcg subcutaneous, 500 to 1,500 mcg oral). Most users complete full 8-week cycles without interruption.
  • Skin inflammation improvement at higher subcutaneous doses. Psoriasis and eczema users report visible changes by week 4 to 6; GHK-Cu stacking is the common protocol for this application.

KPV: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 10 key studies·Preclinical

Preclinical-only evidence.

Dosing studied: 200–1,000 mcg/day SC (extrapolated from mouse models); oral requires 2–3× SC dose
Read the evidence (key study, limitations)

KPV inhibits NF-κB and suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in mouse colitis models via PepT1-mediated cellular uptake. Zero completed human clinical trials. No human PK, dose-finding, or efficacy data exist.

Key Study

Gastroenterology 2008 (PMID 18061177): PepT1-mediated KPV uptake reduces intestinal inflammation in mouse colitis model

Limitations

No human trials. All dose estimates are extrapolated from rodent data. No human PK study: half-life (~30 min) is inferred from α-MSH family literature. FDA explicitly states no human exposure data for any administration route.

Community Experience
Moderate
3.5/5
Based on low: ~15 KPV-specific PubMed papers

Used primarily for gut inflammation (IBD, IBS, Crohn's, UC, leaky gut).

Community dosing: SC: 200–500 mcg/day; Oral: 500–1,500 mcg/day (2–3× SC dose)
Read the reports (what users report 5, common issues 5)

Oral route preferred for GI-specific use based on PepT1 rationale. Slow onset (4–8 weeks); not an acute pain reliever. Generally well-tolerated. Sourcing quality is the main practical concern.

What users report (5)
  • Gut inflammation relief (colitis, IBS, leaky gut): most consistent community report
  • Reduced bloating and GI discomfort within 2–4 weeks
  • Skin inflammation improvement (psoriasis, eczema) at higher doses
  • Oral dosing option: uncommon for peptides; enables targeted GI delivery without injection
  • Good tolerability: minimal side effects reported at standard doses
Common issues (5)
  • Slow onset (4–8 weeks): users expect faster relief; many quit before therapeutic effect
  • Oral vs. SC dose confusion: most reports fail to differentiate; oral requires 2–3× SC dose
  • Product quality variability: wide COA/purity range; budget products (<$35/5mg) lack HPLC documentation
  • Not an acute pain reliever: does not replace NSAIDs for immediate symptom control
  • Herxheimer-like reactions in first 1–2 weeks reported by some IBD users (managed by slow titration)
Partially Aligned

Community use closely mirrors the preclinical rationale: PepT1-targeted oral delivery for gut inflammation, NF-κB suppression over weeks. The mechanism supports what the community is doing, but the dosing is entirely extrapolated: no human trial confirms efficacy, optimal dose, or safety. Alignment is on mechanism/route logic, not on validated clinical outcomes.

KPV Dosage Guide

SpeculativeVery limited human data: dose based on preclinical and anecdotal reports
LevelDose / InjectionFrequency
Beginner200 mcg
DailyTrack
Moderate500 mcg
DailyTrack
Aggressive1 mg
DailyTrack
Note:

Start with the oral route if your goal is gut inflammation. The PepT1 transporter preferentially absorbs KPV in inflamed intestinal tissue, which is the whole point for IBD, IBS, and colitis.

Reconstitution math for injectable: a 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg/mL. For a 200 mcg dose, pull 8 units on a U-100 insulin syringe. For 500 mcg, pull 20 units.

Oral dosing requires 2 to 3 times the subcutaneous dose. A 500 mcg oral dose delivers less active peptide to systemic circulation than 500 mcg subcutaneous. Account for GI degradation.

Take oral KPV 30 minutes before food on an empty stomach. Dietary dipeptides compete at the PepT1 transporter, and eating too soon reduces uptake.

The thing most beginners miss: this is not a fast-acting anti-inflammatory. KPV suppresses NF-kB upstream, not prostaglandin synthesis like NSAIDs. Expect 4 to 6 weeks for meaningful improvement. Running less than 4 weeks probably won't show you the full picture.

Calculate your KPV dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

KPV Protocols by Goal

beginnerCommunity8 weeks on, 4–8 weeks off
Titration
Wk 1–2
250 mcg · Once daily · Oral (capsule or reconstituted solution)
Maintenance
Wk 3–8
500 mcg · Once daily · Oral (capsule or reconstituted solution)

Expected: Reduced gut pain, improved stool consistency, decreased bloating by weeks 3–4; meaningful flare reduction and mucosal healing by weeks 6–8.

Monitor: Track stool consistency, pain scores, bloating frequency. Fecal calprotectin useful if accessible. Improvement should be detectable by week 6.

How to Use KPV

  1. 1
    Step 1

    Gather supplies: 5 mg KPV vial, 2 mL bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 or 30 gauge, 0.5 inch needle).

  2. 2
    Clean the tops of both vials with alcohol swabs

    Draw 2 mL bacteriostatic water and inject slowly into the KPV vial, directing the stream against the glass wall. Do not shake. Swirl gently until the powder dissolves completely.

  3. 3
    This gives you a concentration of 2,500 mcg per mL

    For common doses: 200 mcg equals 8 units on a U-100 syringe; 250 mcg equals 10 units; 500 mcg equals 20 units; 1,000 mcg equals 40 units.

  4. 4
    Step 4

    For subcutaneous injection: pinch a fold of skin on the abdomen or outer thigh. Insert the needle at a 45-degree angle. Inject slowly and hold for 5 seconds before withdrawing. Rotate injection sites daily.

  5. 5
    Step 5

    For oral use: draw the desired dose into a syringe (no needle), squirt into the mouth and swallow on an empty stomach. Alternatively, use pre-made oral capsules if available. Take 30 minutes before food.

  6. 6
    Inject or take orally once daily, ideally in the morning

    For the advanced flare protocol (1,000 mcg total), split into 500 mcg morning and 500 mcg evening, 8 to 12 hours apart.

  7. 7
    Step 7

    Store reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks of reconstitution.

Alternative Routes

Oral capsule or solution

2–3× the SC dose required (500–1,500 mcg/day oral vs. 200–500 mcg/day SC) due to partial GI degradation and transit losses. PepT1 upregulation in inflamed tissue enhances intestinal uptake: a natural targeting mechanism.

Take on empty stomach (30 min pre-meal) to reduce competitive inhibition at PepT1 transporter by dietary dipeptides. No human oral bioavailability study exists: dose recommendation is mechanistically supported but empirically unvalidated.

Subcutaneous injection

200–500 mcg/day (beginner–moderate); 500–1,000 mcg/day split doses (advanced/acute flare). Near-complete SC absorption assumed.

Provides systemic inflammatory coverage: skin, joints, gut (systemically). Does not provide the PepT1-targeted local GI delivery advantage of oral route.

Topical (iontophoresis / formulated cream)

Topical application studied in psoriasis, dermatitis, wound healing research. No established community dosing: iontophoresis delivery explored in published literature (ScienceDirect); not currently a standard community protocol.

Topical is not one of KPV's main routes, which are subcutaneous and oral. Published evidence for iontophoresis and microneedle delivery exists: primarily for localized skin anti-inflammatory effect. Community use via raw peptide in a cream base is occasionally reported but lacks standardization.

Sublingual spray

Some community users report sublingual spray as providing "more systemic" effect than oral capsule. No bioavailability data. Dose typically mirrors SC dose (200–500 mcg).

Bitter taste commonly reported with sublingual spray. No formal comparison to oral capsule or SC injection.

Mixing your own vial? Use the KPV reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

KPV Stacking Protocols

Works With

Avoid

Thymosin Alpha-1 (TA-1)

Potential additive immune suppression/modulation. KPV suppresses inflammatory cytokines; TA-1 is an immune stimulator/modulator. Stacking may create unpredictable immune signaling, especially risky in autoimmune conditions. Limited interaction data.

Biologics / immunosuppressants (methotrexate, azathioprine, anti-TNF agents)

Potential additive immunosuppressive effect. KPV reduces TNF-α, IL-1β, IL-6: the same targets as many IBD biologics. Combined use without physician oversight risks over-suppression of immune response and increased infection risk.

Do not combine
Corticosteroids (prednisone, budesonide)

Overlapping anti-inflammatory pathways. Both suppress NF-κB and inflammatory cytokines via different mechanisms. No direct interaction data; monitor for additive immune suppression in combined use.

How much does KPV cost?

Typical price

$4.00 to $6.00 per mg

Typical $5.00

Middle half of 118 US prices for 10 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Not currently available from compounding pharmacies. Listed as withdrawn from Category 2 as of April 22, 2026. PCAC discussed it on July 23, 2026; no FDA rule has added it to the 503A bulks list.

Pricing updated 2026-04-09

KPV Side Effects

The biggest safety concern with KPV is the unknown. Zero completed human clinical trials exist. No human pharmacokinetic data. No dose-finding study. The FDA has explicitly stated it lacks human exposure information for any administration route. Every safety profile below comes from preclinical research and community reporting, not from controlled human trials.

That said, the community tolerability signal is remarkably clean. Most users report no side effects at standard doses (200 to 500 mcg subcutaneous, 500 to 1,500 mcg oral). KPV is a naturally occurring tripeptide fragment, three amino acids long, which limits the immunogenicity risk that larger synthetic peptides carry.

Herxheimer-like reactions in weeks 1 to 2. This is the most commonly reported negative experience, specifically among IBD and Crohn's patients. Gut symptoms temporarily worsen before improving. The community explanation is that rapid NF-kB suppression shifts the inflammatory milieu. Slow titration from 250 mcg manages this in most cases.

Injection site reactions with subcutaneous administration. Mild redness and irritation at the injection site, consistent with other peptide injections. KPV has a short plasma half-life (~30 minutes), so daily injection site rotation across abdomen and thigh areas is the standard recommendation. If irritation persists despite rotation, switching to oral dosing is the typical approach.

Potential immune over-suppression with concurrent medications. KPV reduces TNF-alpha, IL-1beta, and IL-6, the same cytokine targets as many IBD biologics (infliximab, adalimumab) and immunosuppressants (methotrexate, azathioprine). Stacking KPV with these medications without physician oversight risks additive immune suppression and increased infection susceptibility. This is the one genuinely serious risk in the community use pattern.

Oral-specific: mild bitter taste reported with sublingual spray formulations. Some users note transient GI discomfort at higher oral doses (above 1,000 mcg), though this typically resolves within the first week.

No hepatotoxicity, nephrotoxicity, or cardiovascular effects have been reported in preclinical literature or community use. No antibody formation or receptor desensitization mechanism has been identified.

Pregnancy and breastfeeding: no safety data exists. Do not use. This applies to both oral and injectable forms.

Children and adolescents under 18: not studied in any context. No pediatric dosing exists.

Active malignancy: KPV suppresses immune surveillance pathways (NF-kB, inflammatory cytokines). Effects on tumor immune response have not been studied. Avoid until data exists.

When to stop: if gut symptoms worsen and persist beyond the 2-week titration window, discontinue or reduce dose. If you experience signs of immune suppression (frequent infections, slow wound healing), stop immediately and consult a physician. If injection site reactions do not resolve with rotation, switch to oral or discontinue.

Common Issues & Solutions

No gut improvement at 4 weeks: confirm oral dose is 2–3× the SC dose (not equal); many users under-dose oral KPV. Also confirm empty-stomach timing: PepT1 transporter competes with dietary dipeptides.

Herxheimer-like reaction in week 1–2 (worsening gut symptoms): common in IBD users; reduce to 250 mcg/day and titrate slowly over 4 weeks rather than starting at full dose.

Injection site irritation: rotate sites each injection; KPV has a short half-life (~30 min estimated) so consistent daily injection site rotation across abdomen and thigh is important.

Expecting acute pain relief: KPV is not an NSAID. It suppresses upstream inflammatory signaling (NF-κB), not prostaglandin synthesis. Response is gradual: minimum 4 weeks. Do not compare to ibuprofen-like relief.

No response at 8 weeks (SC): consider switching to oral route if GI-specific condition: PepT1 upregulation in inflamed tissue provides preferential uptake; systemic SC may not concentrate sufficiently in colonic epithelium.

Ask AI about this page

Ask AI for a second opinion on KPV dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no human safety data in these populations
  • Known hypersensitivity to KPV or α-MSH-derived peptides
  • Active malignancy: effects on tumor immune surveillance not studied
  • Children and adolescents under 18: not studied in pediatric populations
  • Concurrent immunosuppressive therapy: potential for additive immune suppression

Drug Interactions

  • Immunosuppressants (methotrexate, azathioprine, biologics): potential additive immune suppression; monitor closely
  • NSAIDs: while KPV may protect against NSAID-induced gut damage, combined anti-inflammatory effects should be monitored
  • Corticosteroids: overlapping anti-inflammatory pathways; no direct interaction known but monitor for over-suppression of immune response
  • Aminosalicylates (mesalamine, sulfasalazine): no known interaction; may provide complementary benefit for IBD patients
  • Anticoagulants: no known interaction, but monitor for injection site bruising with injectable form

Product Quality

Recommended Monitoring

TestWhenTarget
Fecal calprotectinBaseline and week 6–8<50 µg/g (normal); <200 µg/g (clinical remission threshold for IBD)
C-reactive protein (CRP) / hsCRPBaseline and week 6<1.0 mg/L (optimal); <3.0 mg/L (acceptable)
Complete blood count (CBC) with differentialBaseline; repeat at week 8 if concurrent immunosuppressant useNot listed
ESR (erythrocyte sedimentation rate)Optional: baseline and week 8Not listed
Subjective symptom diary (pain, stool consistency, bloating frequency)Weekly throughout protocolNot listed
Fecal calprotectin

Quantitative marker of intestinal inflammation: most direct measure of KPV gut efficacy. Elevated in UC and Crohn's; should decrease with effective treatment.

C-reactive protein (CRP) / hsCRP

Systemic inflammatory marker. Less gut-specific than calprotectin but broadly useful. Should decrease with KPV's NF-κB suppression.

Complete blood count (CBC) with differential

Monitor for immune modulation effects, especially lymphocyte and neutrophil counts, if stacking with LL-37 or TA-1, or if on concurrent IBD medications.

ESR (erythrocyte sedimentation rate)

Secondary systemic inflammatory marker; less sensitive than CRP but useful corroboration.

Subjective symptom diary (pain, stool consistency, bloating frequency)

Most practical tracking tool in absence of labs. Establishes trend; useful to determine response before labs are ordered.

KPV Before and After

Weeks 1-2

Body adjusts to the peptide. Some users report reduced bloating and mild improvement in GI comfort within the first week. Establish consistent daily dosing routine.

Weeks 2-4

Anti-inflammatory effects become noticeable. Reduced gut pain, improved stool consistency, and decreased bloating reported by most users. Inflammatory markers may begin to improve.

Weeks 4-6

Significant reduction in gut inflammation symptoms. Users with colitis or IBS typically report meaningful improvement in flare frequency and severity. Mucosal healing is underway.

Weeks 6-8

Peak therapeutic benefit for most users. Gut barrier integrity improves. Systemic inflammatory markers (CRP, calprotectin) often show measurable reduction. Skin inflammation also improves if present.

Weeks 8+

Maintenance phase. Most protocols recommend cycling off after 8 weeks. Benefits typically persist for several weeks after discontinuation. Repeat cycles as needed for flare management.

What to Expect

Weeks 1 to 2, Tolerance establishment. Your body is adjusting. KPV begins entering inflamed intestinal cells via PepT1 uptake, and NF-kB suppression starts at the cellular level. Don't expect visible results yet. Some users notice subtle bloating reduction in the first week. IBD patients may experience a Herxheimer-like flare, where symptoms temporarily worsen before improving. Mild injection site redness is normal with subcutaneous dosing; higher oral doses can cause transient GI discomfort. Slow titration from 250 mcg manages the Herxheimer response.

Weeks 2 to 4, Early anti-inflammatory effect. Sustained NF-kB suppression begins reducing downstream cytokine production. TNF-alpha, IL-1beta, and IL-6 output should be falling. Most users report reduced gut pain, improved stool consistency, and less frequent bloating during this window. CRP levels may start normalizing. Side effects from the first two weeks typically resolve. Some oral users mention a mild bitter taste with sublingual spray.

Weeks 4 to 6, Meaningful inflammation reduction. Preclinical models show measurable intestinal inflammation reduction by this point. Epithelial apoptosis decreases and barrier integrity starts recovering. Community reports align: IBD and IBS flare frequency and severity drop noticeably. Users treating skin conditions (psoriasis, eczema) alongside gut inflammation also report visible improvement.

Weeks 6 to 8, Peak therapeutic benefit. Full mucosal healing and barrier restoration in preclinical models. CRP and fecal calprotectin often show measurable decreases. Most IBD users describe meaningful quality-of-life improvement by now. Skin anti-inflammatory effects become visible. Some users extend to 10 or 12 weeks if they're responding well and tolerating the peptide.

Weeks 8 and beyond, Cycling off and maintenance. No long-term human data exists. Preclinical models suggest anti-inflammatory effects persist after discontinuation; no receptor desensitization has been identified. Community reports confirm benefits lasting several weeks after the cycle ends. Standard recommendation: 4 to 8 week break, then repeat if needed. Some users run a 5-on, 2-off weekly pattern for extended maintenance.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

KPV uptake via PepT1 begins in inflamed tissue; NF-κB suppression initiates. No measurable clinical endpoint expected this early.

Community

Subtle reduction in bloating reported by some users. Herxheimer-like reactions possible in IBD patients (worsening before improvement). Most report little to no change.

Weeks 2–4
Science

Sustained NF-κB suppression should begin reducing downstream cytokine production (TNF-α, IL-1β, IL-6). Mucosal inflammation reduction starts.

Community

Reduced gut pain, improved stool consistency, decreased bloating reported by majority. Inflammatory markers (CRP) may begin to normalize.

Weeks 4–6
Science

Significant reduction in intestinal inflammation in mouse models by this point. Epithelial apoptosis reduced; barrier integrity improving.

Community

Significant improvement in IBD/IBS flare frequency and severity. Skin inflammation (psoriasis, eczema) also improving in users treating both conditions.

Weeks 6–8
Science

Full mucosal healing and barrier restoration in preclinical models. Systemic inflammatory markers (CRP, calprotectin) measurably reduced.

Community

Peak benefit period. Most IBD users report meaningful quality-of-life improvement. Skin anti-inflammatory effects visible. Some users extend to 10–12 weeks if responding well.

Weeks 8+
Science

No long-term human data. Preclinical: anti-inflammatory effects persist post-discontinuation. No receptor desensitization mechanism identified.

Community

Benefits reported to persist several weeks after cycle ends. Most protocols recommend 4–8 week break then repeat if needed. 5-on/2-off weekly cycling used by some for extended maintenance.

Pharmacokinetics

Half-Life
30min
Bioavailability
Oral: absorbed intact via PepT1 transporter in inflamed intestinal tissue; SC: near-complete absorption
Tmax
~15-30 minutes (SC); variable for oral depending on GI transit
Data Confidence
low

Source: Estimated from rapid plasma degradation kinetics of small tripeptides; KPV has a plasma half-life under 30 minutes but exerts prolonged intracellular effects via PepT1 uptake (PMID 18061177)

Pharmacokinetics: Active Dose Over Time

t½ = ~30 min plasma (functional anti-inflammatory activity persists 4-6 hours)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
3
Molecular Weight
342.43 Da
Sequence
KPV
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 67727-97-3

Who Should Consider KPV

  • Adults with inflammatory bowel disease (ulcerative colitis or Crohn's)
  • Individuals with chronic gut inflammation, IBS, or leaky gut syndrome
  • Adults seeking targeted intestinal anti-inflammatory support
  • Patients with skin inflammatory conditions (dermatitis, psoriasis)
  • Adults recovering from GI infections or antibiotic-related gut damage

Related Peptides

What Changed for KPV

  1. Regulatory

    PCAC backed KPV for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  2. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations

References

  1. [1]PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (Mol Ther 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed

Additional References

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C for long-term stability. At 2-8°C, stable 6-12 months sealed.
After Reconstitution
Refrigerate at 2-8°C, use within 3-4 weeks. Oral capsules: room temperature in sealed container.
Temperature
-20°C long-term; 2-8°C short-term

Frequently Asked Questions

For localized gut inflammation (ulcerative colitis, IBS), oral is actually the better choice. KPV enters colonic epithelial cells via the PepT1 transporter, which is upregulated in inflamed intestinal tissue; creating a natural targeting effect. SC gives more systemic coverage. Oral dose should be 2-3x the SC dose (500-1,500 mcg/day) to account for GI degradation.

Most users report subtle GI improvement at 2-3 weeks, meaningful improvement at 4-6 weeks. KPV suppresses upstream NF-kB signaling; it's not an acute pain reliever. Expect a gradual, cumulative effect. Running less than 4 weeks probably won't show the full picture.

Yes, and it's the most discussed KPV stack for good reason. BPC-157 drives mucosal tissue repair while KPV reduces the inflammatory signaling cascade. Complementary pathways. Multiple integrative medicine clinics recommend this combination for IBD/IBS.

KPV survives GI transit partly thanks to the PepT1 transporter, which actively imports small peptides across intestinal epithelium. Mouse colitis models show significant disease reduction with oral KPV. The caveat: no human oral bioavailability study exists. The mechanism supports absorption, especially in inflamed tissue where PepT1 is upregulated.

For SC: start at 200-250 mcg/day, titrate to 500 mcg for moderate inflammation. For oral: use 2-3x the SC dose; 500-750 mcg/day starting, up to 1,500 mcg/day for active flares. These are community-derived ranges; no human dose-finding trials exist.